1. Critical conversations in Public-private partnerships Dr Ranjana Kumar 1 st November 2007

2. The GAVI Alliance  Public-private partnership bringing together all the major stakeholders in immunization  Launched in 2000  Mission: Save children’s lives and protect people’s health by increasing access to immunization in poor countries  Vaccines and funding to strengthen immunization and health services to 70+ of the poorest countries 2

3. GAVI partners

4. Outline of innovations  Raising resources – International Financing Facility for Immunisation, IFFIm  Making vaccines available – Advance Market Commitment, AMC  Facilitating introduction of new vaccines, ADIPs  Supporting policy and programme implementation, Civil Society Organisation partnerships  Programme level impact

5. Funding innovations  IFFIm: International Finance Facility for Immunisation: using markets differently – a radical shift in scale – US$ 1 billion frontloaded from the capital markets  AMC: Advance market commitment pilot for pneumoccocal vaccine: accelerating access

6. PPP example: Immunization Services Support (ISS) Success factors  Monetary resources  Incentivisation principals  Economically minded and committed governments  Rigorous control instance (e.g. independent audit of immunization coverage data to ensure system integrity) Lessons learnt  New performance based approaches (e.g. performance based funding) in development  significantly increase its efficiency  positively affects people’s commitment through increased self- determination Partner Contribution Public Sector  Funds managed by governments Public and Social Sector  Implementation: Delivery of immunization service in local hospitals or health centres run by local NGOs Private Sector  Expertise: e.g. business based funding approaches Social Sector  Advise: The WHO and UNICEF (renewable partner in GAVI Alliance Board) e.g. supported the Ministry of Health of Cambodia with the application process for ISS funds  Implementation: UNICEF is managing the transfer of ISS funds Background and Objectives  Performance-based and time limited funding for developing countries to improve their health outcomes (i.e. increased vaccination coverage)  ISS money is highly flexible to use; governments and its development partners make local decisions on most effective allocation and use of ISS funds to strengthen their health systems  Additional funding or performance payments are given to countries when they have met or surpassed their self set immunization goals after the investment phase (almost similar to sales representatives receiving a commission bonus after having met their targets)

7. Results: Speeding availability GAVI established HepB - all developing countries HepB containing combination vaccines 198319851987198919911993199519971999200120032005 Hep B licensed HepB combos licensed Millions of doses 0 50 100 150 200 GAVI was designed to reduce the time lag in the availability of vaccines between industrialised and developing countries

8. Results: influencing the market Vaccine prices drop as new manufacturers enter the market DPT Hep B vaccines prices have declined by 40%

9. The growing role of the developing country vaccine manufacturer Presence of multiple suppliers in the market is critical to vaccine security. In 2006, almost 30% of all the vaccines purchased by UNICEF for GAVI were manufactured in developing countries.

10. Results to date Health services  Additional children reached  Hepatitis B: 126 million  Hib: 20 million  Yellow fever: 17 million  DTP3: 28 million  Dramatic immunisation coverage increase  DPT3: 63% in 1999 to 77% in 2006  44% in 1999 to a 73% in 2006 in Africa  Safe (auto-disable) syringes uptake  1.2 billion syringes

11.  Estimated additional children reached with GAVI support (cumulative 2001- 06)  Hepatitis B: 126 million  Hib: 20 million  DTP3: 28 million  Yellow Fever: 17 million Progress to date 1.7 million cumulative deaths already averted It is projected that, by end 2006, more than 2.3 million future deaths will have been prevented (600,000 in 2006 alone).

12. GAVI prospects and priorities A long-term vaccine investment strategy Ensuring effective implementation of scaled up resources Build on the PPP model and strengthened CSOs participation in GAVI policy-making and programme implementation Linking GAVI in with developments in international health architecture and in particular health systems work Maintaining GAVI’s position as a leading innovative Global Health Partnership

13. External validation of the GAVI Alliance business model  “The economic impact and benefits of immunisation have been greatly underestimated; GAVI programmes could earn a rate of return of 18 percent” David Bloom, David Canning and Mark Weston (Harvard School of Public Health) “The Value of Vaccination”, World Economics, September 2005  “This is the first time that there is hard evidence that one of the major global health programmes is having a real impact.” "Independent Evaluation of the Impact of GAVI on DTP3 Coverage,” Murray et al. The Lancet, 18 September, 2006